Oragenics (OGEN) 14.19M Share Common Offering at $0.37/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Boeing nears approval of 737 MAX anti-ice fix, paving way for deliveries
Oragenics Prices $5.25 Million Common Stock Offering
November 20, 2020 8:30 AM ESTTAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company), a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced the pricing of an underwritten public offering of 14,189,189 shares of its common stock at a price to the public of $0.37 per share. The gross proceeds to the Company from this offering are expected to be approximately $5,250,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Oragenics has granted the underwriters a 45-day option to purchase up to an... More
